Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment

Jordan, Karin; Kasper, Christoph; Schmoll, Hans‐Joachim

doi:10.1016/j.ejca.2004.09.026

Cited by 122 publications

(94 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy-induced nausea and vomiting can be classified into three categories: (1) acute onset, occurring within 24 h of the initial chemotherapy administration; (2) delayed onset, occurring 24 h to several days after the initial treatment; and (3) anticipatory nausea and vomiting (Jordan et al 2005). Anticipatory nausea (AN) develops in response to chemotherapy treatments, in which cytotoxic drugs are delivered in the presence of a novel context (hospital sights, sounds, smells and tastes).…”

Section: Introductionmentioning

confidence: 99%

The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat

et al. 2007

View full text Add to dashboard Cite

Rationale Anticipatory nausea (AN) experienced by chemotherapy patients is resistant to current anti-nausea treatments. In this study, the effect of manipulation of the endocannabinoid (EC) system on a rat model of nausea (conditioned gaping) was determined. Objective The potential of cannabidiol (CBD) and the fatty acid amide hydrolase (FAAH) inhibitor, URB597 (URB) to reduce conditioned gaping in rats were evaluated. Materials and methods In each experiment, rats received four conditioning trials in which they were injected with lithium chloride immediately before placement in a distinctive odor-laced context. During testing, in experiment 1, rats were injected with vehicle (VEH), 1, 5 or 10 mg/kg CBD 30 min before placement in the context previously paired with nausea and in experiment 2, rats were injected with VEH, 0.1 or 0.3 mg/kg URB 2 h before placement in the context. Additional groups evaluated the ability of the CB 1 antagonist/inverse agonist, SR141716A, to reverse the suppressive effects of URB. Experiment 3 measured the potential of URB to interfere with the establishment of conditioned gaping.Results When administered before testing, CBD (1 and 5, but not 10 mg/kg) and URB (0.3, but not 0.1 mg/kg) suppressed conditioned gaping. The effect of URB was reversed by pre-treatment with the CB 1 antagonist/inverse agonist, SR141716A. When administered before conditioning, URB also interfered with the establishment of conditioned gaping. Conclusions Manipulations of the EC system may have therapeutic potential in the treatment of AN.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This prevention is focused on the entire period of emetic risk which is 4 days for patients who received highly or moderately emetogenic chemotherapy [22,29]. This could be perfectly achieved by understanding the mechanisms of these antiemetic drugs either alone or in combination so as to get their maximum benefit [30].…”

Section: Nausea and Vomiting Treatment Optionsmentioning

confidence: 99%

“…Combination antiemetic treatment becomes the standard regimen used for the control of nausea and vomiting caused by chemotherapy [30]. The different types of treatments are as follows: Serotonin-receptor antagonists (5-HT 3 ), Dopamine-2-receptor antagonists, Corticosteroids, Neurokinin-1-recptor antagonists, Cannabinoids & Benzodiazepines [29].…”

Section: Nausea and Vomiting Treatment Optionsmentioning

confidence: 99%

Supportive and Palliative Care in Solid Cancer Patients

Hassan¹,

Yusoff²,

Othman³

2013

Cancer Treatment - Conventional and Innovative Approaches

View full text Add to dashboard Cite

“…On the other hand, the mechanism at the delayed phase is poorly understood. 6,8) Therefore several anti-emetic treatments are advocated: Dexamethasone (DEX), 5-HT 3 antagonist, DEX＋5-HT 3 antagonist, DEX＋neu-rokinin-1 receptor antagonist, or metoclopramide. 3 5) 5-HT 3 antagonists are without doubt the most eŠec-tive antiemetics against acute nausea and emesis.…”

Section: Introductionmentioning

confidence: 99%

“…3,4) The platinum chemotherapeutic agents, cisplatin (CDDP) and carboplatin (CBDCA) are categorized in high (emesis risk ＞90％ without antiemetics) and in moderate (emesis risk 30 90％ without antiemetics), respectively. 3,4) The physiological mechanisms underlying nausea and emesis are considered to be diŠerent at the acute phase, occurring within 24 hours after chemotherapy, and the delayed phase, occurring 24 hours to several days after chemotherapy. Serotonin 5-HT 3 receptor antagonist is deˆnitely recommended against acute nausea and emesis because serotonin plays a main role at the acute phase.…”

Section: Introductionmentioning

confidence: 99%

Preventive Effects of Low-dose Dexamethasone for Delayed Adverse Events Induced by Carboplatin-based Combination Chemotherapy

et al. 2007

View full text Add to dashboard Cite

We performed a retrospective study to examine the protective eŠect of low-dose dexamethasone (DEX) on delayed adverse events induced by carboplatin (CBDCA)-based combination chemotherapy in patients with thoracic tumors. Low-dose DEX (4 8 mg/day) was administered on day 1 and after, in addition to a serotonin 5-HT 3 receptor antagonist. The acute adverse events (day 1) were well controlled in the patients with or without co-treatment of DEX. On the other hand, the delayed nausea, emesis, anorexia, and fatigue after day 2 failed to be controlled by 5-HT 3 antagonist alone. Co-treatment with DEX signiˆcantly suppressed the grade of the delayed adverse events during days 2 10. The mean ratio of complete protection during days 2 10 were signiˆcantly higher in the DEX-treated group compared with the non-DEX-treated group. These results reveal that low-dose DEX is a clinically eŠective treatment for the prevention of delayed adverse events induced by CBDCA-based combination chemotherapy.

show abstract

Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment

Cited by 122 publications

References 21 publications

The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat

The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat

Supportive and Palliative Care in Solid Cancer Patients

Preventive Effects of Low-dose Dexamethasone for Delayed Adverse Events Induced by Carboplatin-based Combination Chemotherapy

Contact Info

Product

Resources

About